StemCells (STEM) Bullish Stance Reiterated at Maxim Group on Positive Spine Paralysis Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
StemCells (STEM) Provided Data on Phase I/II Trial in Spinal Cord Injury
May 19, 2014 8:10 AM EDTStemCells, Inc. (Nasdaq: STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients.
The presentation included the first data on AIS B subjects to be transplanted in the Phase I/II chronic... More
StemCells (STEM) Posts Q1 Results and Data Is Coming, Maxim Group Says
May 15, 2014 7:39 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $2.50 price target on StemCells (NASDAQ: STEM) following first quarter results and an overall update on the current clinical programs with a focus on PI/II spine and AMD trials.
The analyst... More
